Evidence map›Paper›PMID 40899648›Full record

ArticleAmerican journal of epidemiology2026

REFINE2: a simplified simulation tool to help epidemiologists evaluate the suitability and sensitivity of effect estimation within user-specified data.

Xiang Meng, Jonathan Y Huang

Abstract read
In one paragraph

Article in American journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xiang MengDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, United States.ORCID 0009-0000-7502-1314
Jonathan Y HuangDepartment of Public Health Sciences, Thompson School of Social Work & Public Health, University of Hawaii at Manoa, Honolulu, HI, United States.ORCID 0000-0002-5901-8403

Funding

The Role of gp120 on Cardiovascular Disease in People Living with HIVU54MD007601 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI Benjamin C. Fogelgren · 2017 to 2026
$59.5M
Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)U24MD015970 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI Sandra Perreira Chang, Elizabeth O. Ofili · 2020 to 2026
$20.6M
TR&D3 - Rapid Translation of AI-powered Temporally Precise mHealth Interventions via Efficient and Embeddable Trustworthy Biomarker ImplementationsP41EB028242 · NIBIB · UNIVERSITY OF MEMPHIS · PI Santosh Kumar · 2020 to 2026
$9.5M
Data-Based Methods for Just-In-Time Adaptive Interventions in Alcohol UseR01AA023187 · NIAAA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MURPHY, SUSAN A · 2015 to 2019
$2.6M
NIAAA NIH HHS R01 AA023187NIBIB NIH HHS P41 EB028242NIH HHS 2U54MD007601 and U24MD015970NIMHD NIH HHS U24 MD015970NIMHD NIH HHS U54 MD007601Singapore National Medical Research Council MOH-000550-00 (MOH-OFYIRG19nov-0008)U.S. National Institutes of Health R01AA23187 and P41EB028242
6 · The paper itself

Abstract

Epidemiologists have access to various methods to reduce bias and improve statistical efficiency in effect estimation, from standard multivariable regression to state-of-the-art doubly-robust efficient estimators paired with highly flexible, data-adaptive algorithms ("machine learning"). However, due to numerous assumptions and trade-offs, epidemiologists face practical difficulties in recognizing which method, if any, may be suitable for their specific data and hypotheses. Importantly, relative advantages are necessarily context-specific (data structure, algorithms, model misspecification), limiting the utility of universal guidance. Evaluating performance through real-data-based simulations is useful but out-of-reach for many epidemiologists. We present a user-friendly, offline Shiny app REFINE2 (Realistic Evaluations of Finite sample INference using Efficient Estimators) that enables analysts to input their own data and quickly compare the performance of different algorithms within their data context in estimating a prespecified average treatment effect (ATE). REFINE2 automates plasmode simulation of a plausible target ATE given observed covariates and then examines bias and confidence interval coverage (relative to this target) given user-specified models. We present an extensive case study to illustrate how REFINE2 can be used to guide analyses within epidemiologist's own data under three typical scenarios: residual confounding; spurious covariates; and mis-specified effect modification. As expected, the apparent best method differed across scenarios and are suboptimal under residual confounding. REFINE2 may help epidemiologists not only chose amongst imperfect models, but also better understand common underappreciated problems, such as finite sample bias using machine learning.

Indexed as

Computer SimulationAlgorithmsBiasData Interpretation, StatisticalEpidemiologic MethodsHumansMachine LearningModels, Statisticalcausal inferenceconfoundingmachine learningplasmode simulationsensitivity analyses

Identifiers

PMID40899648
PMCPMC13368598

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.